Sibenadet

Drug Profile

Sibenadet

Alternative Names: AR-C68397; AR-C68397AA; ARL 68397; C 68397; FPL 68397; Viozan™

Latest Information Update: 28 Jun 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca R&D Charnwood
  • Developer AstraZeneca Pharmaceuticals; AstraZeneca R&D Charnwood
  • Class Small molecules; Thiazoles
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Jun 2001 Discontinued-I for Asthma in United Kingdom (Inhalation)
  • 28 Jun 2001 Discontinued-III for Chronic obstructive pulmonary disease in Europe (Inhalation)
  • 28 Jun 2001 Discontinued-III for Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top